IMDX vs TMO
IMDX: iMDx develops decentralized molecular diagnostic kits for transplant organ rejection monitoring using donor-derived cell-free DNA biomarkers, enabling in-house testing at hospitals rather than centralized lab services. TMO: Thermo Fisher Scientific is a global leader in serving science, providing an extensive portfolio of analytical instruments, laboratory equipment, and mission-critical consumables for the life sciences and healthcare industries.
Side-by-side fundamentals
| Metric | IMDX | TMO | Edge |
|---|---|---|---|
| Price as of 2026-07-27 close | $4.70 | $559.53 | |
| Market cap as of 2026-07-31 | $147M | $207.9B | |
| P/E as of 2026-07-31 | n/a | 30.20 | |
| PEG as of 2026-07-31 | n/a | 2.89 | |
| Net margin as of 2026-07-31 | -2454.6% | +15.0% | TMO higher |
| Gross margin as of 2026-07-31 | +51.3% | +40.9% | IMDX higher |
| Operating margin as of 2026-07-31 | -2500.7% | +17.6% | TMO higher |
| ROE as of 2026-07-31 | -426.7% | +13.3% | TMO higher |
| ROA as of 2026-07-31 | -119.1% | +6.3% | TMO higher |
| Debt / equity as of 2026-07-31 | 0.92 | 0.81 | TMO lower |
| Revenue growth (YoY) as of 2026-07-31 | -49.3% | +7.2% | TMO higher |
| Revenue CAGR (3y) SEC XBRL | +61.8% | -0.3% | IMDX higher |
| Dividend yield as of 2026-07-31 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | n/a | 5 | |
| Beta as of 2026-07-31 | 1.87 | 0.82 | |
| 1-year return as of 2026-07-27 close | +62.9% | +17.0% | IMDX higher |
Fundamentals: market data, as of 2026-07-31. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-07-27.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.